ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME: CHOOSING THE BASIS MEDICATION
The aim of the study was to assess the effectiveness of Accupro (Quinapril; 40 mg/d), as monotherapy and basis medication of combined therapy, in the treatment of arterial hypertension (AH) among patients with metabolic syndrome (MS). After 8 weeks of Accupro monotherapy (40 mg/d), target levels of...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2011-04-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1148 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849410246947110912 |
|---|---|
| author | M. V. Lebedeva |
| author_facet | M. V. Lebedeva |
| author_sort | M. V. Lebedeva |
| collection | DOAJ |
| description | The aim of the study was to assess the effectiveness of Accupro (Quinapril; 40 mg/d), as monotherapy and basis medication of combined therapy, in the treatment of arterial hypertension (AH) among patients with metabolic syndrome (MS). After 8 weeks of Accupro monotherapy (40 mg/d), target levels of blood pressure (BP) were achieved in 68% of the patients. BP normalization correlated with endothelial function improvement. Accupro therapy (40 mg/d) was also well tolerated. Accupro (40 mg/d) could be recommended as an effective and safe basis medication for combined antihypertensive therapy in patients with AH and MS. |
| format | Article |
| id | doaj-art-beccab47bc924de38b478564b8d1eecd |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2011-04-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-beccab47bc924de38b478564b8d1eecd2025-08-20T03:35:11Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202011-04-01024953952ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME: CHOOSING THE BASIS MEDICATIONM. V. Lebedeva0Кафедра терапии и профболезней ПМГМУ им. И.М. СеченоваThe aim of the study was to assess the effectiveness of Accupro (Quinapril; 40 mg/d), as monotherapy and basis medication of combined therapy, in the treatment of arterial hypertension (AH) among patients with metabolic syndrome (MS). After 8 weeks of Accupro monotherapy (40 mg/d), target levels of blood pressure (BP) were achieved in 68% of the patients. BP normalization correlated with endothelial function improvement. Accupro therapy (40 mg/d) was also well tolerated. Accupro (40 mg/d) could be recommended as an effective and safe basis medication for combined antihypertensive therapy in patients with AH and MS.https://russjcardiol.elpub.ru/jour/article/view/1148arterial hypertensionmetabolic syndromeentodelin-1albuminuriaquinapril |
| spellingShingle | M. V. Lebedeva ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME: CHOOSING THE BASIS MEDICATION Российский кардиологический журнал arterial hypertension metabolic syndrome entodelin-1 albuminuria quinapril |
| title | ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME: CHOOSING THE BASIS MEDICATION |
| title_full | ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME: CHOOSING THE BASIS MEDICATION |
| title_fullStr | ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME: CHOOSING THE BASIS MEDICATION |
| title_full_unstemmed | ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME: CHOOSING THE BASIS MEDICATION |
| title_short | ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME: CHOOSING THE BASIS MEDICATION |
| title_sort | antihypertensive therapy in patients with metabolic syndrome choosing the basis medication |
| topic | arterial hypertension metabolic syndrome entodelin-1 albuminuria quinapril |
| url | https://russjcardiol.elpub.ru/jour/article/view/1148 |
| work_keys_str_mv | AT mvlebedeva antihypertensivetherapyinpatientswithmetabolicsyndromechoosingthebasismedication |